Clinical Trials
18 trialsNCT03620019 2026-03-27
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03839459 2026-01-28
Denosumab for Smoldering Multiple Myeloma
University of Rochester
Phase 2 Completed
NCT04907539 2025-04-16
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
Redx Pharma Ltd
Phase 2 Completed
NCT04907851 2025-03-17
KEYNOTE-E86
Redx Pharma Ltd
Phase 2 Completed
NCT02613416 2024-08-23
Dmab
Stony Brook University
Phase 2 Completed
NCT02470091 2024-01-22
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
Children's Oncology Group
Phase 2 Completed
NCT00396279 2022-11-08
Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone
Amgen
Phase 2 Completed
NCT00680992 2022-09-22
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
Amgen
Phase 2 Completed
NCT01951586 2021-10-25
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Amgen
Phase 2 Completed
NCT02366130 2021-10-07
Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01545648 2020-01-02
Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer
University of California, San Francisco
Phase 2 Terminated
NCT01952054 2019-11-22
Denosumab for Breast Cancer With Bone Mets
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02758132 2019-11-08
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
University of Hawaii
Phase 2 Terminated
NCT03070002 2018-11-20
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
Northwestern University
Phase 2 Terminated
NCT00896454 2018-10-17
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Amgen
Phase 2 Completed
NCT00259740 2017-03-15
Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
Amgen
Phase 2 Completed
NCT00091832 2014-01-28
Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer
Amgen
Phase 2 Completed
NCT00104650 2011-01-24
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Amgen
Phase 2 Completed